
William G. Wright
Examiner (ID: 13821)
| Most Active Art Unit | 1106 |
| Art Unit(s) | 1106, 1754 |
| Total Applications | 637 |
| Issued Applications | 554 |
| Pending Applications | 0 |
| Abandoned Applications | 83 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19170784
[patent_doc_number] => 20240156758
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => METHOD OF INITIATING AND ESCALATING SOTALOL HYDROCHLORIDE DOSING
[patent_app_type] => utility
[patent_app_number] => 18/417748
[patent_app_country] => US
[patent_app_date] => 2024-01-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5754
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 460
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18417748
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/417748 | METHOD OF INITIATING AND ESCALATING SOTALOL HYDROCHLORIDE DOSING | Jan 18, 2024 | Pending |
Array
(
[id] => 19417295
[patent_doc_number] => 20240293418
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-05
[patent_title] => COMBINATION THERAPY FOR TREATING CANCER
[patent_app_type] => utility
[patent_app_number] => 18/411139
[patent_app_country] => US
[patent_app_date] => 2024-01-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 45516
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18411139
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/411139 | COMBINATION THERAPY FOR TREATING CANCER | Jan 11, 2024 | Abandoned |
Array
(
[id] => 20371197
[patent_doc_number] => 12478611
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-11-25
[patent_title] => Pharmaceutical composition for oral administration of edaravone and method of administering same
[patent_app_type] => utility
[patent_app_number] => 18/398241
[patent_app_country] => US
[patent_app_date] => 2023-12-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 4
[patent_no_of_words] => 11341
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 238
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18398241
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/398241 | Pharmaceutical composition for oral administration of edaravone and method of administering same | Dec 27, 2023 | Issued |
Array
(
[id] => 19571769
[patent_doc_number] => 20240376061
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-11-14
[patent_title] => HETEROCYCLIC GLP-1 AGONISTS
[patent_app_type] => utility
[patent_app_number] => 18/534517
[patent_app_country] => US
[patent_app_date] => 2023-12-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 75651
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18534517
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/534517 | Heterocyclic GLP-1 agonists | Dec 7, 2023 | Issued |
Array
(
[id] => 19111177
[patent_doc_number] => 20240122927
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE
[patent_app_type] => utility
[patent_app_number] => 18/528976
[patent_app_country] => US
[patent_app_date] => 2023-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10567
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18528976
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/528976 | METHODS FOR TREATING HEMOLYTIC DISEASES AND SICKLE CELL DISEASE | Dec 4, 2023 | Abandoned |
Array
(
[id] => 19111146
[patent_doc_number] => 20240122896
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-04-18
[patent_title] => LASOFOXIFENE COMBINATION TREATMENT OF ER+ BREAST CANCER THAT HAS PROGRESSED ON A CDK4/6 INHIBITOR
[patent_app_type] => utility
[patent_app_number] => 18/529368
[patent_app_country] => US
[patent_app_date] => 2023-12-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25445
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -26
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18529368
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/529368 | LASOFOXIFENE COMBINATION TREATMENT OF ER+ BREAST CANCER THAT HAS PROGRESSED ON A CDK4/6 INHIBITOR | Dec 4, 2023 | Abandoned |
Array
(
[id] => 19065617
[patent_doc_number] => 20240100043
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => DOSING REGIMEN FOR INJECTABLE CETIRIZINE
[patent_app_type] => utility
[patent_app_number] => 18/520024
[patent_app_country] => US
[patent_app_date] => 2023-11-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12590
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -7
[patent_words_short_claim] => 151
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18520024
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/520024 | DOSING REGIMEN FOR INJECTABLE CETIRIZINE | Nov 26, 2023 | Pending |
Array
(
[id] => 19049205
[patent_doc_number] => 20240091174
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => Method Of Treating Major Depressive Disorder
[patent_app_type] => utility
[patent_app_number] => 18/517062
[patent_app_country] => US
[patent_app_date] => 2023-11-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12318
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18517062
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/517062 | Method of treating major depressive disorder | Nov 21, 2023 | Issued |
Array
(
[id] => 19504922
[patent_doc_number] => 12116333
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-10-15
[patent_title] => 3,3'-(hydrazine-1,2-diyl)bis(1-(naphthalen-2-yloxy)propan-2-ol) as an ecofriendly insecticidal agent against spodoptera littoralis (boisd.)
[patent_app_type] => utility
[patent_app_number] => 18/511800
[patent_app_country] => US
[patent_app_date] => 2023-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 2976
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18511800
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/511800 | 3,3'-(hydrazine-1,2-diyl)bis(1-(naphthalen-2-yloxy)propan-2-ol) as an ecofriendly insecticidal agent against spodoptera littoralis (boisd.) | Nov 15, 2023 | Issued |
Array
(
[id] => 19196328
[patent_doc_number] => 11993554
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-05-28
[patent_title] => 3,3'-(hydrazine-1,2-diyl)bis(1-(naphthalen-2-yloxy)propan-2-ol) as an ecofriendly insecticidal agent against
[patent_app_type] => utility
[patent_app_number] => 18/511426
[patent_app_country] => US
[patent_app_date] => 2023-11-16
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 2948
[patent_no_of_claims] => 1
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 45
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18511426
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/511426 | 3,3'-(hydrazine-1,2-diyl)bis(1-(naphthalen-2-yloxy)propan-2-ol) as an ecofriendly insecticidal agent against | Nov 15, 2023 | Issued |
Array
(
[id] => 20451788
[patent_doc_number] => 12514831
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-01-06
[patent_title] => Method of treating major depressive disorder
[patent_app_type] => utility
[patent_app_number] => 18/508826
[patent_app_country] => US
[patent_app_date] => 2023-11-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8012
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 147
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18508826
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/508826 | Method of treating major depressive disorder | Nov 13, 2023 | Issued |
Array
(
[id] => 19226662
[patent_doc_number] => 12006295
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-06-11
[patent_title] => 4,5-bis(4-bromophenyl)-2-(4-bromophenyl)-1-hexyl-1H-imidazole as an antimicrobial compound
[patent_app_type] => utility
[patent_app_number] => 18/387918
[patent_app_country] => US
[patent_app_date] => 2023-11-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4250
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 23
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18387918
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/387918 | 4,5-bis(4-bromophenyl)-2-(4-bromophenyl)-1-hexyl-1H-imidazole as an antimicrobial compound | Nov 7, 2023 | Issued |
Array
(
[id] => 19257958
[patent_doc_number] => 12017999
[patent_country] => US
[patent_kind] => B1
[patent_issue_date] => 2024-06-25
[patent_title] => 1-[4,5-bis(4-chlorophenyl)-1-hexyl-1H-imidazol-2-yl]-2-naphthol as an antimicrobial compound
[patent_app_type] => utility
[patent_app_number] => 18/503823
[patent_app_country] => US
[patent_app_date] => 2023-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 4113
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 8
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18503823
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/503823 | 1-[4,5-bis(4-chlorophenyl)-1-hexyl-1H-imidazol-2-yl]-2-naphthol as an antimicrobial compound | Nov 6, 2023 | Issued |
Array
(
[id] => 19049258
[patent_doc_number] => 20240091227
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-21
[patent_title] => Use Of 2-Phenyl-6-(1H-Imidazol-1-YL) Quinazoline For Treating Neurodegenerative Diseases, Preferably Alzheimer's Disease
[patent_app_type] => utility
[patent_app_number] => 18/387577
[patent_app_country] => US
[patent_app_date] => 2023-11-07
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6731
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -6
[patent_words_short_claim] => 56
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18387577
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/387577 | Use Of 2-Phenyl-6-(1H-Imidazol-1-YL) Quinazoline For Treating Neurodegenerative Diseases, Preferably Alzheimer's Disease | Nov 6, 2023 | Pending |
Array
(
[id] => 19202742
[patent_doc_number] => 20240174641
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-30
[patent_title] => HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING
[patent_app_type] => utility
[patent_app_number] => 18/493126
[patent_app_country] => US
[patent_app_date] => 2023-10-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25878
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 21
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18493126
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/493126 | HETEROCYCLIC COMPOUNDS CAPABLE OF ACTIVATING STING | Oct 23, 2023 | Pending |
Array
(
[id] => 19032394
[patent_doc_number] => 20240082209
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-14
[patent_title] => COMPOSITIONS AND METHODS FOR TREATING PAIN WITH WOGONIN
[patent_app_type] => utility
[patent_app_number] => 18/491644
[patent_app_country] => US
[patent_app_date] => 2023-10-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10985
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18491644
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/491644 | Compositions and methods for treating pain with wogonin | Oct 19, 2023 | Issued |
Array
(
[id] => 20561992
[patent_doc_number] => 12564582
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2026-03-03
[patent_title] => Use of pridopidine for treating dystonias
[patent_app_type] => utility
[patent_app_number] => 18/489846
[patent_app_country] => US
[patent_app_date] => 2023-10-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 64
[patent_no_of_words] => 15042
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 193
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18489846
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/489846 | Use of pridopidine for treating dystonias | Oct 18, 2023 | Issued |
Array
(
[id] => 19170796
[patent_doc_number] => 20240156770
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-16
[patent_title] => HIGH PENETRATION PRODRUG COMPOSITIONS OF RETINOIDS AND RETINOID-RELATED COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 18/488616
[patent_app_country] => US
[patent_app_date] => 2023-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 15427
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18488616
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/488616 | HIGH PENETRATION PRODRUG COMPOSITIONS OF RETINOIDS AND RETINOID-RELATED COMPOUNDS | Oct 16, 2023 | Pending |
Array
(
[id] => 19003578
[patent_doc_number] => 20240067649
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-29
[patent_title] => NLRP3 MODULATORS
[patent_app_type] => utility
[patent_app_number] => 18/488092
[patent_app_country] => US
[patent_app_date] => 2023-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35333
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 1313
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18488092
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/488092 | NLRP3 modulators | Oct 16, 2023 | Issued |
Array
(
[id] => 18987680
[patent_doc_number] => 20240059649
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-02-22
[patent_title] => SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS
[patent_app_type] => utility
[patent_app_number] => 18/488215
[patent_app_country] => US
[patent_app_date] => 2023-10-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12281
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 24
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18488215
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/488215 | SUBSTITUTED N-ACETYL-L-CYSTEINE DERIVATIVES AND RELATED COMPOUNDS | Oct 16, 2023 | Pending |